Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
415
Views
4
CrossRef citations to date
0
Altmetric
Author's View

Getting by with a little help from the right CD4+ T cells

Sabine Hoepner Centre of Oncology, Geneva University Hospitals and University of Geneva; Geneva, Switzerland
&
Paul R Walker Centre of Oncology, Geneva University Hospitals and University of Geneva; Geneva, SwitzerlandCorrespondence[email protected]
Article: e25772 | Received 15 Jul 2013, Accepted 16 Jul 2013, Published online: 29 Jul 2013

References

  • Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269 - 81; http://dx.doi.org/10.1038/nri3191
  • Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17:1603 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-10-2563
  • Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135:1042 - 54; http://dx.doi.org/10.1093/brain/aws042
  • Lanzavecchia A. Immunology. Licence to kill. Nature 1998; 393:413 - 4; http://dx.doi.org/10.1038/30845
  • Slingluff CL Jr.. The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination?. Cancer J 2011; 17:343 - 50; http://dx.doi.org/10.1097/PPO.0b013e318233e5b2
  • Hoepner S, Loh JM, Riccadonna C, Derouazi M, Maroun CY, Dietrich PY, et al. Synergy between CD8 T Cells and Th1 or Th2 Polarised CD4 T Cells for Adoptive Immunotherapy of Brain Tumours. PLoS ONE 2013; 8:e63933; http://dx.doi.org/10.1371/journal.pone.0063933
  • Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci 2009; 1174:18 - 23; http://dx.doi.org/10.1111/j.1749-6632.2009.04932.x
  • Wang LX, Shu S, Disis ML, Plautz GE. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 2007; 109:4865 - 76; http://dx.doi.org/10.1182/blood-2006-09-045245
  • Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368 - 77; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322
  • Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y. Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. OncoImmunology 2013; 2:e23430; http://dx.doi.org/10.4161/onci.23430

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.